Perinatal hypoxic-ischemic damage: overview and current treatment possibilities

Title:

Perinatal hypoxic-ischemic damage: overview and current treatment possibilities

Creator:

Frajewicki, Ari, Laštůvka, Zdeněk, Borbélyová, Veronika, Khan, Sami, Jandová, Kateřina, Janišová, Kateřina, Otáhal, Jakub, Mysliveček, Jaromír, and Riljak, Vladimír

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:a45f8e06-8682-402c-9265-c959a70fe541
uuid:a45f8e06-8682-402c-9265-c959a70fe541
doi:10.33549/physiolres.934595

Subject:

hypoxia, hypoxic-ischemic encephalopathy, immature brain, and treatment

Type:

model:article and TEXT

Format:

počítač and online zdroj

Description:

Neonatal hypoxic-ischemic encephalopathy is a disorder with heterogeneous manifestation due to asphyxia during perinatal period. It affects approximately 3-12 children per 1000 live births and cause death of 1 million neonates worldwide per year. Besides, motor disabilities, seizures, impaired muscle tone and epilepsy are few of the consequences of hypoxic-ischemic encephalopathy. Despite an extensive research effort regarding various treatment strategies, therapeutic hypothermia with intensive care unit supportive treatment remains the only approved method for neonates who have suffered from moderate to severe hypoxicischemic encephalopathy. However, these protocols are only partially effective given that many infants still suffer from severe brain damage. Thus, further research to systematically test promising neuroprotective treatments in combination with hypothermia is essential. In this review, we discussed the pathophysiology of hypoxic-ischemic encephalopathy and delved into different promising treatment modalities, such as melatonin and erythropoietin. However, preclinical studies and clinical trials are still needed to further elucidate the mechanisms of action of these modalities.

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Coverage:

S379-S401

Source:

Physiological research | 2020 Volume:69 | Number:Supplement 3

Harvested from:

CDK

Metadata only:

false